Archive | BIOTRONIK

BIOTRONIK - Archive

2021
03
February
2021
| 12:13 Europe/Amsterdam
I più recenti modelli di Apple iPhone includono una matrice di magneti più forte rispetto ai modelli precedenti. Un recente studio1 pubblicato sull’ HeartRhythm journal ha segnalato la sospensione della terapia in un iPhone 12 posto a stretto contatt...
Read more
01
February
2021
| 14:18 Europe/Amsterdam
Den senaste modellen av Apple iPhones har en starkare magnetspänning än de tidigare modellerna. I en nyligen genomförd studie(1) som publicerades i HeartRhythm journal påvisades att terapier avbröts när en iPhone 12 kom i nära kontakt med specifika i...
Read more
01
February
2021
| 10:45 Europe/Amsterdam
Recent data from the investigator-initiated, randomized controlled trial (RCT), BIOLUX AV, showed that the treatment of patients with dysfunctional hemodialysis access (HA), with BIOTRONIK’s Passeo®-18 LuxTM drug-coated balloon (DCB)*, is safe and ef...
Read more
29
January
2021
| 10:56 Europe/Amsterdam
En yeni Apple iPhone serisi, önceki modellere göre daha güçlü bir manyetik etkiye sahiptir. HeartRhythm Journal’da yayınlanan yeni bir çalışma1, bir iPhone 12'nin belirli bir implante edilen kardiyoverter defibrilatör (ICD) cihazıyla yakın teması hal...
Read more
28
January
2021
| 19:14 Europe/Amsterdam
The most recent series of Apple iPhones include a stronger magnetic array than previous models. A recent study1 published in the HeartRhythm Journal reported that therapy was suspended when an iPhone 12 was brought into close contact with specific im...
Read more
2020
09
December
2020
| 10:34 Europe/Amsterdam
Electrophysiologists in Europe will now have access to state-of-the-art, gold-tipped force sensing ablation catheters following the BIOTRONIK announcement today that AlCath Force is CE-market approved. With the release of the unique catheter, a full ...
Read more
17
September
2020
| 08:57 Europe/Amsterdam
Outcomes of the BIO4AMB trial presented at the CIRSE 2020 Summit demonstrated that ambulatory treatment with 4­‑French (4F) devices is a valid and safe option for endovascular treatment of lower extremity peripheral artery disease (PAD). The 4F compa...
Read more
07
September
2020
| 08:45 Europe/Amsterdam
BIOTRONIK today announced European market release of the Passeo®‑35 Xeo PTA (percutaneous transluminal angioplasty) balloon catheter. Compared to other available PTA balloons1, the device offers physicians improved crossability, excellent trackabilit...
Read more
01
September
2020
| 16:12 Europe/Amsterdam
A new study1 presented at this year’s European Society of Cardiology (ESC) Congress today shows that BIOTRONIK’s exclusive Closed Loop Stimulation (CLS) helps reduce unexplained fainting in patients with recurrent episodes due to skipped heartbeats. ...
Read more
01
September
2020
| 07:00 Europe/Amsterdam
Cardiologists balancing increasing workload pressures and time demands in their clinics, have from today access to a new injectable cardiac monitor (ICM). BIOMONITOR IIIm is equipped with a unique algorithm that significantly reduces false positive a...
Read more
14
July
2020
| 09:55 Europe/Amsterdam
BIOTRONIK is proud to announce the availability of its next-generation balloon-expandable cobalt chromium iliac stent system, Dynetic®-35. When compared to leading competitors, the new peripheral stent has up to 14 times greater flexibility and up to...
Read more
19
June
2020
| 20:50 Europe/Amsterdam
CardioMessenger devices form an essential part of BIOTRONIK’s remote monitoring system, enabling the secure transmission of critical patient and device data to the treating physician. As the company that pioneered remote monitoring, we have taken cyb...
Read more
16
June
2020
| 12:50 Europe/Amsterdam
BIOTRONIK has today announced its commitment to giving physicians additional tools to pace in the His-Bundle, coinciding with the launch of its His-Bundle Pacing (HBP) tools in a limited number of centers starting now with a full launch later in 2020...
Read more
20
May
2020
| 16:00 Europe/Amsterdam
BIOTRONIK and Acutus Medical today announced a new alliance to provide a comprehensive portfolio of electrophysiology, mapping, ablation and accessory products for catheter-based treatment of cardiac arrhythmias across select markets, including Europ...
Read more
13
May
2020
| 13:30 Europe/Amsterdam
Results just published in Circulation Arrhythmia and Electrophysiology confirm that BIOTRONIK Home Monitoring® provides safe and cost-effective remote management of pacemaker patients,1 indicating that it can safely replace the common practice of rou...
Read more
06
May
2020
| 09:24 Europe/Amsterdam
According to recently presented TICO trial data, patients with acute coronary syndrome (ACS) treated with BIOTRONIK’s Orsiro® drug eluting stent (DES) benefit from stopping aspirin three months after stenting and continuing only with ticagrelor monot...
Read more
31
March
2020
| 10:18 Europe/Amsterdam
As the COVID-19 pandemic continues, we are conscious of the enormous strain that you are all under. We share your concerns about the spread of the virus and the disruption it is causing globally. We are doing what we can to help minimize this disrupt...
Read more
04
March
2020
| 14:02 Europe/Amsterdam
The US Food and Drug Administration has issued a Safety Communication regarding a family of cybersecurity vulnerabilities known as SweynTooth, which may introduce risks for certain medical devices that use Bluetooth Low Energy (BLE) wireless communic...
Read more
24
February
2020
| 00:00 Europe/Amsterdam
BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinfo...
Read more
21
February
2020
| 14:11 Europe/Amsterdam
BIOTRONIK has announced CE Mark certification for the Orsiro® Mission drug-eluting stent (DES) system. The next generation of the company’s ultrathin strut Orsiro DES provides higher deliverability than other contemporary stents.1 Orsiro Mission is n...
Read more
27
January
2020
| 00:00 Europe/Amsterdam
BIOTRONIK, Inc. today announced the appointment of David Hayes, MD, FACC, as Chief Medical Officer. Dr. Hayes will oversee the development of BIOTRONIK’s cardiovascular solutions with a focus on advancing unique, proven innovations that help physicia...
Read more
23
January
2020
| 00:00 Europe/Amsterdam
BIOTRONIK this month announced the market release of its new injectable cardiac monitor (ICM), BIOMONITOR III. The novel device is designed to help patients with irregular heart rhythms by documenting unexplained syncope with increased clarity. As...
Read more
2019
30
October
2019
| 00:00 Europe/Amsterdam
BIOTRONIK announced today that its Orsiro® coronary drug-eluting stent (DES) has been approved for sale in China by the National Medical Products Administration. The company expects to make the device available to Chinese patients and physicians in t...
Read more
04
October
2019
| 15:31 Europe/Amsterdam
On October 1, the US Food and Drug Administration (FDA) issued a Safety Communication regarding a set of cybersecurity vulnerabilities, referred to as “Urgent/11” that — if exploited by a remote attacker — may introduce risks for medical devices and ...
Read more
30
September
2019
| 00:00 Europe/Amsterdam
Full cohort data from the BIOSOLVE-IV registry strengthen the clinical evidence for BIOTRONIK’s Magmaris®1 Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery disease. Dr. Stefan Verheye, Senior Interventional Ca...
Read more
18
September
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced that it is the world’s first manufacturer to receive European Medical Device Regulation (MDR) certification for a Class III (highest risk) medical device. Following a successful conformity assessment, BIOTRONIK also obtained...
Read more
11
September
2019
| 00:00 Europe/Amsterdam
Twelve-month results of the BIOFLEX COF trial have demonstrated that the implantation of stents with low chronic outward force1 (COF) was associated with less neointimal hyperplasia2, consequently resulting in less restenosis. Patients treated with B...
Read more
02
September
2019
| 00:00 Europe/Amsterdam
BIOTRONIK’s ultrathin Orsiro® stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at 12 months, according to newly released data from the BIOSTEMI trial.1 Today Dr. Juan Fernando Iglesias, Geneva University Hospital...
Read more
12
August
2019
| 15:37 Europe/Amsterdam
The work ‘Security Testing of the Pacemaker Ecosystem’ was recently published as a master’s thesis, authored by Mr. Anders Been Wilhelmsen and Mr. Eivind Skjelmo Kristiansen. This publication investigates the state of cybersecurity of BIOTRONIK’s ICS...
Read more
31
July
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the company’s PK Papyrus® covered coronary stent system1 has been named a finalist in the 2019 Prix Galien USA Awards Ceremony for Best Medical Technology. PK Papyrus is used in emergency situations to create a physical b...
Read more